Mass Spectrometric Mapping of the DNA Adductome as a Means to Study Genotoxin Exposure, Metabolism, and Effect. by Hemeryck, LY et al.
	 1	
Mass spectrometric mapping of the DNA adductome as a means to 
study genotoxin exposure, metabolism and effect  
Lieselot Y. Hemeryck1, Sharon A. Moore2, and Lynn Vanhaecke1,* 
 
1Laboratory of Chemical Analysis, Department of Veterinary Public Health and Food Safety, Faculty of 
Veterinary Medicine, Ghent University, Merelbeke, 9820, Belgium  
2School of Pharmacy and Biomolecular Sciences, Faculty of Science, Liverpool John Moores 
University, Liverpool, L3 3AF, United Kingdom 
*To whom correspondence should be addressed. Address: Salisburylaan 133, B-9820 Merelbeke, Belgium; Tel: 
+32(0)92647457; Fax: +32(0)92647492; Email: lynn.vanhaecke@ugent.be 	
 
ABSTRACT  
Covalent binding of endo- or exogenous chemicals to DNA results in the formation of DNA adducts 
which are reflective of exposure of the human body to DNA-damaging molecules and their metabolic 
pathways. The study of DNA adduct types and levels in human tissue therefore offers an interesting 
tool in several fields of research, including toxicology and cancer epidemiology. Over the years, a 
range of techniques and methods have been developed to study the formation of endo- and 
exogenous DNA adducts. However, for the simultaneous detection, identification and quantification of 
both known and unknown DNA adducts, mass spectrometry (MS) is deemed to be the most promising 
technique. In this perspective, we focus on the analysis of multiple DNA adducts within a sample with 
the emphasis on untargeted analysis. The advantageous use of MS methodologies for DNA 
adductome mapping is discussed comprehensively with relevant field examples. In addition, several 
aspects of study design, sample pretreatment and analysis are addressed as these factors 
significantly affect the reliability of DNA adductomics studies. 
 
INTRODUCTION 
Although the underlying pathways are not fully understood, years of epidemiological research have 
demonstrated that approximately 90% of cancer deaths can be attributed to the presence of certain 
environmental factors, and not genetics.1,2 Unfortunately, assessment of human exposure to the large 
spectrum of environmental factors and the direct or indirect role in disease onset and development 
has proven to be a challenge. In 2005, Wild introduced the ‘exposome’ as a complementary concept 
to the ‘genome’, a concept which originated at least 10 years earlier.3 The exposome encompasses 
all of the encountered exposures of a certain individual over the course of his or her lifetime, from the 
very early stages of conception and embryonic development through to adulthood, old age and death. 
In contrast to the individual genome, which is set at conception, the individual exposome evolves 
continuously throughout one’s life.1-4  
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In light of genotoxicity and carcinogenicity studies, the DNA adductome, which consists of all DNA 
adduct types and levels present in a certain DNA sample, and can be considered as a part of the 
exposome, is of particular interest. DNA adducts originate from the interaction and subsequent 
covalent bonding between an electrophilic molecule and nucleophilic sites in DNA (i.e. 
nucleobases).5,6 The majority of DNA reactive molecules have the potential to lead to mutations and 
chromosomal alterations during DNA replication via formation of DNA adducts or DNA strand breaks, 
thus possibly resulting in carcinogenesis later on.7 Therefore, DNA adduct formation is deemed to be 
the first step in chemically induced carcinogenesis.5 However, whilst carcinogenesis due to genotoxin 
exposure and DNA adduct formation poses a convincing hypothesis, at the present time only a limited 
number of studies have successfully demonstrated a positive association between certain DNA 
adduct levels and cancer incidence i.e. ‘biomarkers of effect’. In consequence, one may question the 
relevance of DNA adduct analysis in cancer risk assessment. Nonetheless, the association between, 
for example, aflatoxin B1 exposure and hepatocellular carcinoma8, and the long undoubted 
association between tobacco smoking and cervical cancer9 clearly demonstrate the merit of DNA 
adduct analysis in cancer risk assessment. Overall, evidence for the association between DNA 
adducts and cancer risk is accumulating.10,11 Hence, the need for a fit-for-purpose analytical approach 
to study DNA adduct formation in different pathways has presented itself, along with the need to 
assemble all acquired knowledge on DNA adduct formation in a comprehensive database. 
A multitude of analytical methods have been developed and optimized for the detection of DNA 
adducts in different biological matrices ranging from those based on antibodies and labeling such as 
immunoassays, immunohistochemistry and 32P-postlabeling to advanced instrumental techniques. 
The latter invariably use chromatographic separation coupled with various detection methods e.g. gas 
chromatography-electron capture detection (GC-ECD), high performance liquid chromatography-
fluorescence detection (HPLC-FD), GC- or (HP)LC-mass spectrometry ((HP)LC-MS), (LC-)nuclear 
magnetic resonance ((LC-)NMR), and accelerator MS (AMS).12,13 The characteristic advantages of 
MS, currently recognized as the gold standard for DNA adduct detection, have been reviewed and 
argued in the past.6,12,14 In this paper, we further explore the potential of DNA adductomics studies to 
map the DNA adductome. In light of this, the tools at hand and several important aspects of DNA 
adductomic studies, including the issue of DNA adduct and internal standard stability, sample 
preparation, analysis of target vs. surrogate tissue, method validation and study design are discussed 
comprehensively. Moreover, the promising use of MS as a tool for DNA adductomic studies focusing 
on the detection and identification of both known and unknown DNA adducts in the exposome is 
highlighted, explained and demonstrated with recent examples.  
 
DNA ADDUCT ANALYSIS AS A MEANS TO STUDY GENOTOXIN EXPOSURE, METABOLISM 
AND EFFECT 
DNA adducts originate from exposure of cellular DNA to both endo- and exogenous genotoxins.  
Tissues and cells are exposed to endogenously generated chemicals through several 
(patho)physiological processes on a daily basis, including attack of DNA by reactive oxygen and 
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carbonyl species, lipid peroxidation products, estrogens and S-adenosylmethionine (gene expression 
regulator and methyl donor).15 However, the exogenous exposure to xenobiotics is deemed more 
important in toxicology and cancer risk assessment.16 Examples of exogenous DNA adduct formation 
consists of DNA damage by dietary toxins such as mycotoxins, acrylamide and heterocyclic amines 
(HAAs).17-19 Of course, several other environmental lifestyle factors can also significantly contribute to 
genotoxin exposure and exogenous DNA adduct formation; e.g. smoking, alcohol, certain industrial 
occupations and living conditions.20-22  
The direct measurement of genotoxic chemicals in body tissues and fluids does not take into account 
important factors such as interindividual differences in exposure, absorption and distribution. 
Moreover, these chemicals may have a rapid turnover in the body, making direct measurement 
impossible. Hence, DNA adductome mapping offers a more thorough view of the different biological 
pathways involved in genotoxin exposure. This is especially pertinent since individual heterogeneity in 
genotoxin metabolism and DNA repair specifically complicates a straightforward assessment of the 
effect of certain genotoxins. Accordingly, holistic assessment of all DNA adduct types and levels 
(‘mapping’) provides a more appropriate tool to study the biological effect of a genotoxic chemical. 
The arguments raised above demonstrate the fact that DNA adducts show great potential as 
‘biomarkers of exposure’ or ‘biomarkers of internal dose’. Furthermore, since DNA adducts represent 
the amount of genotoxin that ‘successfully’ reached the DNA molecule in a certain individual, they can 
even act as a ‘biomarker of the biological effective dose’ of a certain genotoxic substance for that 
particular individual.10,11  
Although interpretation of DNA adduct formation is complicated by several interfering factors, the 
field of DNA adductomics shows great potential in different areas of research. DNA adductome 
mapping does not only enable research into genotoxin exposure, but can also provide information on 
interindividual differences in genotoxin detoxification or activation. For example, Haugen and 
colleagues demonstrated a gender related difference in susceptibility to DNA adduct formation in 
tobacco smokers due to a significantly higher expression level of lung cytochrome P450 1A1 in 
women.23 Genetic polymorphisms in DNA repair can also be a source of interindividual variation in 
DNA adduct levels11; e.g. Xia and co-workers recently published research on interindividual 
differences in aflatoxin B1 DNA adduct formation due to certain genetic polymorphisms in a DNA 
repair gene.24  
In addition to information on exposure to genotoxins, interindividual differences in genotoxin 
metabolisation and individual susceptibility to DNA damage and repair, DNA adduct analysis also 
provides important evidence on the possible long-term adverse health effects of genotoxic chemicals. 
When DNA adducts are introduced to the DNA sequence, the resulting DNA damage may lead to 
mutagenesis and carcinogenesis.7 There are at least three cases in which a causal link between the 
occurrence of DNA adducts and cancer incidence have been confirmed; firstly, the previously 
acknowledged aflatoxin B1 DNA adducts and their link to hepatocellular carcinoma8; secondly, the 
case of PAH-DNA adducts and cervical cancer9, and thirdly, the link between aristolochic acid 
consumption (via consumption of Aristolochia plants), aristolactam DNA adduct formation  and 
transitional cell (urothelial) carcinoma of the upper urinary tract.25 For many other exo- or endogenous 
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DNA adducts, potential clues for the probable relationship between DNA adduct levels in tissue and 
cancer incidence are accumulating, emphasizing the significance of DNA adduct studies in the field of 
toxicology and cancer epidemiology.10,11 Adductome mapping, like any technique, may not provide the 
full answer but can aid with the elucidation of cancer susceptibility and mechanisms, and potentially 
lead to improved cancer prevention and/or development of treatments for at-risk individuals. In Fig. 1, 
the position of DNA adduct formation in the pathway of genotoxin exposure, metabolism and effect is 
presented to illustrate the potential use of DNA adduct analysis for in-depth assessment of genotoxin 
exposure, metabolism and effect. 
 
 
Figure 1. DNA adducts in relation to genotoxin exposure, metabolism and effect (aflatoxin B1 
associated hepatocarcinogenesis as a case study). 
 
THE UNIQUE POTENTIAL OF DNA ADDUCTOMICS 
Exposomic studies comprise both external and internal exposure assessment in order to correctly link 
a certain exposure to a certain effect2, and this also applies to DNA adductomic studies. The most 
common tool used to study environmental exposure to toxins are questionnaires. However, the major 
flaw of questionnaires in light of exposome mapping, is the fact that they can only focus on a limited 
amount of environmental factors and pollutants. Furthermore, questionnaires do not take into account 
exposure to yet unknown, but possibly also highly relevant environmental factors, and are often 
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subject to participant or response bias.1,2. Therefore, an in-depth exposure assessment requires a 
multi-disciplinary approach that can tackle these issues. 
Focussing on the more detailed assessment of genotoxin exposure by means of analytical 
chemistry, two different types of studies or approaches can be distinguished; the bottom-up (targeted) 
and the top-down (untargeted) approach. The bottom-up approach envisions summing up all known 
exposure types or groups in order to characterize the exposome. The downside to this most 
commonly used approach is the fact that unknown exogenous and also endogenous environmental 
factors may be overlooked.2,26 The alternative strategy on the other hand; the top-down approach, 
reflects both known and unknown exogenous and endogenous exposures.2 Although the latter 
sounds very appealing, it requires specialized untargeted “omics” technologies and methodologies, 
and embodies extensive data processing by means of specialized software. Nevertheless, 
independent experts in the field have suggested that “omics” is the present and future of (cancer) 
epidemiology, despite its expense and complexity.2,4 Therefore, application of these approaches to 
the field of adductomics, via the use of appropriately designed studies and analytical methodologies, 
is worthy of investigation.  
 
MASS SPECTROMETRY AS THE METHOD OF CHOICE FOR DNA ADDUCTOMICS 
DNA adduct analysis requires very sensitive and highly specific analytical techniques and 
methodologies. For years, 32P-postlabeling was the most utilized technique and for some DNA 
adducts types, a sensitivity of 1 adduct per 1010 nucleotides could be achieved.27 Unfortunately, false 
positives and artefacts are common when using this approach.28 MS-based detection techniques on 
the other hand, enable accurate identification of DNA adducts and can also provide structural 
information, in which other analytical methods often fall short. Multiple analytical techniques have 
contributed to the current knowledge on DNA adducts and DNA adduct detection techniques have 
been reviewed extensively in the past.12,13,29 However, it is clear that MS detection excels in specificity 
and structural identification.12-14 More than a decade ago Koc et al. stated that the only disadvantage 
of MS in the field of DNA adduct analysis, was its sensitivity.28 Over the years, sensitivity has 
continued to improve6,14 as different research groups have focused on optimization of DNA adduct 
detection methods with MS30-37, including research into non-manual data mining and sequencing to 
locate DNA adduction sites.38,39 Due to ongoing technical advancements and the use of stable isotope 
labeled internal standards, MS currently offers a reliable tool to measure low DNA adduct levels with 
the highest specificity.12,14,27,28 Coupling of MS with LC by means of the electrospray interface (ESI) 
has enabled analysis of DNA adducts in very complex biological matrices40, whilst avoiding complex 
and labour-intensive sample preparation with derivatization for the initially envisioned use of GC-
couplings.41 
An important advantage of MS, in contrast to all other previously mentioned DNA adduct detection 
methods (besides NMR), is the possibility to detect both ‘targeted’ and ‘untargeted’ DNA adducts by 
means of full scan MS. Targeted DNA adduct detection (also known as ‘profiling’) refers to the 
detection of known types of DNA adducts, which implies that the MS system specifically scans for the 
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presence of certain compounds of interest to assess their presence and abundance, whilst all other 
molecules in the sample are disregarded completely. On the other hand, untargeted analysis (also 
known as ‘fingerprinting’), refers to the detection of all compounds present, even if unknown or 
deemed irrelevant at the time.42 The full scan data obtained of biological samples can be searched for 
the presence of other DNA adduct types (known or unknown) in parallel or retrospectively, providing 
potentially highly relevant additional information. The targeted detection of DNA adducts accords with 
the bottom-up approach, whereas the untargeted mapping or fingerprinting of DNA adducts facilitates 
a top-down approach.  
 
MASS SPECTROMETRIC TOOLS IN USE FOR DNA ADDUCTOMICS  
Triple Quadrupole Tandem Mass Spectrometry 
LC-ESI-tandem MS (LC-MS/MS) by means of triple quadrupoles is currently the most applied 
technique/instrument for the targeted quantification of DNA adducts.31 With LC-MS/MS, mapping of 
the DNA adductome is enabled through monitoring of the constant neutral loss (CNL) of 2’-
deoxyribose (116 Da) from positively ionized 2’-deoxynucleoside adducts. This approach is 
demonstrated for four different adducts in Fig. 2, where the difference between the precursor ion and 
the base peak is always 116 Da.13 One can focus on all [M+H]+ to [M+H - 116]+ transitions by applying 
a full scan approach in Q3, the third quadrupole, or alternatively use selected reaction monitoring 
(SRM) to view [M+H]+ to [M+H - 116]+ transitions in a more narrow, selected range. The narrow range 
of SRM can be compensated by multiple injections of the same sample, which are then analyzed in 
different mass ranges, although this requires more time for analysis.27  
 
 
 
Figure 2. ESI MS/MS mass spectra documenting [M+H]+ to [M+H-116]+ transitions of four DNA 
different adducts; (A) 8-oxo-dG, the main oxidative stress related DNA adduct; (B) M1dG, the main 
malondialdehyde adduct; (C) B[a]PDEdG, the main benzo[a]pyrene diol epoxide DNA adduct; and (D) 
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DiB[a]PDEdG, a dibenzo[a,1]pyrene diol epoxide DNA adduct. Adapted from Farmer, P.B.; Singh, R. 
Mutat. Res.-Rev. Mutat. 2008, 659, 68-76 (ref 13) 13, copyright 2008 Elsevier. 
 
The group of Kanaly et al. was one of the first to develop and apply an LC-MS/MS method for 
mapping of the DNA adductome. Analysis of human lung and esophagus DNA samples revealed the 
possible presence of more than 1000 putative DNA adducts in each tissue type. The use of analytical 
standards and isotope dilution allowed full identification of seven DNA adducts.43,44 This demonstrates 
the vast amount of data that can be generated and the amount of time involved in positively 
identifying the adducts within a particular sample; the analysis itself takes 28 to 60 min. per sample 
and the authors describe that the time required for data processing and confident identification is 
‘manageable’. Examples of similar LC-MS/MS applications include work by several research groups, 
demonstrating the popularity of this type of instrumentation for DNA adductomics.31,45-52 
An alternative approach to monitoring of the mutual loss of 2-deoxyribose, is the detection of 
altered DNA nucleobases instead of altered nucleosides. Inagaki et al. reported the presence of 
characteristic fragment ions for guanine at m/z 152 (≈ protonated guanine) and 135, which 
corresponds to fragmentation of the NH2 group, and for adenine at m/z 136 (≈ protonated adenine) 
and 11935, which is presumably the corresponding fragmentation although the authors did not show 
the data. Confirming part of these findings, Gregson et al. also documented deamination upon 
collision induced fragmentation of protonated guanine53, whilst other independent research groups 
have also reported the occurrence of a product ion with m/z 152 for guanine34,54 and m/z 136 for 
adenine55,56 using different systems and focusing on different DNA adduct types. However, at the 
present time, it is not clear whether those exact same ions are formed upon fragmentation of all 
purine DNA adduct types.  
The aforementioned research demonstrates that tandem MS can reveal hundreds of putative DNA 
adducts in DNA samples and thus holds great potential for biomarker discovery. However, one 
disadvantage of tandem MS/MS is the loss of sensitivity with CNL or the need for SRM transition 
optimization for each different DNA adduct in order to achieve sufficient detection sensitivity with 
pseudo-CNL.27,31 Secondly, since triple quadrupoles only allow low resolution data acquisition, and 
DNA adduct databases providing MS/MS spectra are not available, DNA adduct identity confirmation 
is dependent on the availability of analyte standards or the use of additional analytical techniques. 
This renders triple quadrupole mass measurements to be less suited for untargeted compound 
analysis and confident compound identification compared to high resolution mass spectrometry 
(HRMS), e.g. time of flight (TOF) and orbitrap, which is discussed further on.27 
Ion Trap Mass Spectrometry 
Ion trap MS-analyzers allow multistage scan events (MSn) that provide additional structural 
information. Just like most triple quadrupole methods, ion trap DNA adduct analysis depends on the 
detection of the neutral loss of the 2’-deoxyribose group. Bessette, Turesky and co-workers describe 
the use of a linear ion trap for data-dependent LC-MS3 (DD-CNL-MS3), where first, the detection of a 
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DNA adduct ion (listed in a targeted mass-list) in a limited m/z scan range leads to MS2 acquisition. 
Subsequently, the detection of the [M+H - 116]+ ion amongst the top ten of the most abundant MS2 
ions triggers MS3 fragmentation. Bessette et al. used this acquisition type to study the formation of 
tobacco-associated DNA adducts of certain aromatic amines, HAAs, PAHs and aldehydes in rat livers, 
human hepatocytes and buccal cells.33 MS3 acquisition or multistage MSn scanning in general, seems 
a major advancement compared to MS2 CNL scanning techniques since MSn provides a higher 
specificity and further DNA adduct characterization.27,33 Unmistakable identification with the ion trap 
occurs through evaluation of the MSn product ion spectrum and co-elution with an analytical standard. 
If necessary (e.g. no analytical standard available), the use of additional analytical techniques using 
accurate mass measurements may assist in the identification of unknowns. Co-workers of Bessette 
and Turesky applied the DD-CNL-MS3 approach in research on 4-aminobiphenyl, HAA and 
aristolochic acid-related aristolactam DNA adducts with a clear focus on targeted DNA adduct 
detection.57,58 Pietsch et al. adapted the method described by Bessette et al. to study DNA adduct 
formation by Illudin S, an antitumoral agent. They were able to study known DNA adducts in a colon 
cancer cell line, but were unable to detect or identify any untargeted DNA adducts.59 This suggests 
that although the ion trap and DD-CNL-MS3 method have proven their worth for structural 
characterization, identification and quantitation of (a limited number of) targeted DNA adducts, the low 
resolution methodology appears less suited for holistic, untargeted omics applications, including DNA 
adductomics.60 Fig. 3 demonstrates compound identification by means of MS3 fragmentation patterns 
for three different DNA adducts of the HAA N2-2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) 
(deoxyguanosine-N2-MeIQx, deoxyguanosine-C8-MeIQx, and deoxyadenosine-C8-MeIQx)33 whereby 
the MS3 fragmentation patterns obtained allow confident compound identification.  
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Figure 3. CNL-MS3 product ion spectra of three MeIQx DNA adducts, from HAA exposure, clearly 
showing multiple fragmentations within the adducts; (A) dG-N2-MeIQx, (B) dG-C8-MeIQx, and (C) dA-
N6-MeIQx. Reproduced from Bessette, E. E.; Goodenough, A. K.; Langouet, S.; Yasa, I.; Kozekov, I. 
D.; Spivack, S. D.; Turesky, R. J. Anal. Chem. 2009, 81, 809-819 (ref 33) 33, copyright 2009 American 
Chemical Society. 
 
Time of Flight High Resolution Mass Spectrometry 
TOF instruments are most commonly used for qualitative analysis as a stand-alone instrument, 
although coupling to a second mass spectrometer offers several opportunities for DNA adductomics 
studies. Recently, Giese and co-workers developed a MALDI-TOF/TOF method (MALDI = matrix-
assisted laser desorption/ionization) to enable untargeted DNA adduct detection (preceded by HPLC 
separation), facilitating investigation of unknown DNA adducts. To this purpose they employed a 
tedious but highly profitable sample preparation procedure based on benzoylhistamine labeling of 
altered nucleotides. This approach enabled the specific detection of altered deoxynucleotides with 
increased sensitivity and specificity (noise was reduced due to the use of negative ionization) in a 
semi-quantitative manner.61,62  
By coupling of a TOF-MS to a quadrupole, the resulting hybrid instrument can also be easily 
employed for both identification and quantitation purposes since accurate mass measurements are 
important for confident compound identification and can also eliminate spectral noise due to matrix 
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interferences.40 Esmans, Van den Driessche and colleagues published research63,64 on the use of a 
QTOF instrument for DNA adduct screening and characterization. Unfortunately, and to the best of 
our knowledge, both the use of the QTOF (quadrupole coupled to TOF) and MALDI-TOF/TOF 
instruments for DNA adductome mapping has not been explored further which may be due to the lack 
of available instrumentation in appropriate research laboratories as tandem MS instrumentation has 
been favoured in recent years.  
 
Orbitrap High Resolution Mass Spectrometry 
Orbitrap technology enables very accurate mass detection due to a high resolving power and mass 
accuracy. The technology is particularly suited and implemented for small molecule analysis and 
untargeted omics applications. The orbitrap is often coupled to an ion trap instrument (early on) or a 
quadrupole (later on), but can also be used as a standalone instrument.40  
Recently, Balbo et al. developed a high resolution DD-CNL-MS3 method for DNA adductomics 
purposes, using a linear ion trap-orbitrap system.32 Within the described application, the orbitrap 
ensures accurate mass measurements resulting in determination of possible elemental composition, 
selective identification of DNA adducts and avoidance of false positives. The CNL [M+H]+ to [M+H-
116]+ transition triggers MS3 acquisition, further contributing to molecular structure data and assisting 
with identification of untargeted DNA adducts (demonstrated in Fig. 4). Therefore, this methodology 
appears to be suitable for wider application to adductomics areas of research. 
 
 
Figure 4. Demonstration of the CNL-MS3 high-resolution/accurate mass adductomic approach with an 
O2-POB-dT standard (a tobacco-specific nitrosamine related DNA adduct). (A) MS3 scan event 
triggered by a mass difference of 116.0474 amu between an ion mass in the full scan (C) and an ion 
mass in the corresponding MS2 spectrum (B). (A.1) MS3 spectrum of O2-POB-dT, (C.1) accurate 
mass full scan ion chromatogram of O2-POB-dT (m/z = 390.1660 amu). Reproduced from Balbo, S.; 
Hecht, S. S.; Upadhyaya, P.; Villalta, P. W. Anal. Chem. 2014, 86, 1744-1752 (ref 32) 32, copyright 
2014 American Chemical Society. 
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PERSPECTIVES FOR MASS SPECTROMETRY-BASED DNA ADDUCTOME MAPPING  
Hybrid High Resolution Mass Spectrometry 
For years, triple quads have dominated the field of trace quantitation.40 Yet, when conducting DNA 
adductome mapping, tandem MS encounters some difficulties regarding DNA adduct identification; 
since accurate mass data are not available and, at the time, sufficient knowledge on MS/MS spectra 
of DNA adducts is somewhat lacking. This necessitates that comparison with analytical standards 
and/or the use of other analytical techniques are essential for confident compound identification. High 
resolution MS provides accurate mass measurements and thus more information regarding 
compound mass, elemental composition and identity. New hybrid systems like QTOF and ion trap-
orbitrap may not always surpass triple quadrupole instruments for low level quantitation of DNA 
adducts in terms of peak areas, but full scan HRMS acquisition always results in lower signal to noise 
ratios compared to low resolution MS due to elimination of noise. Therefore, comparable limits of 
detection and limits of quantification for high resolution hybrids and triple quads are definitely within 
reach. In any case, hybrid HRMS systems offer indisputable advantages through accurate mass 
detection, which renders them to be an excellent tool for omics applications.40  
Besides the QTOF64 and linear ion trap-orbitrap instruments32, other hybrid HRMS systems such 
as the quadrupole-orbitrap, quadrupole ion trap-TOF and linear ion trap-fourier transform cyclotron 
resonance MS could be highly accommodating for DNA adductome mapping.65,66 For example, a 
quadrupole-orbitrap instrument like the Q-ExactiveTM can be operated in different acquisition modes; 
full scan MS, selected ion monitoring (SIM) MS, MS2, full scan data dependent MS2 (DD-MS2), SIM-
DD-MS2 and neutral loss DD-MS2 (NL-DD-MS2), enabling different approaches for targeted and 
untargeted analysis of complex biological matrices.67 In particular, the use of NL-DD-MS2 for 
untargeted DNA adduct detection should be explored further as this approach can provide HRMS2 
spectra of DNA adducts characterized by the loss of e.g. 2’-deoxyribose ([M+H]+ to [M+H - 116]+ 
transition) upon fragmentation; a distinctive feature of nucleoside DNA adducts that has been 
commonly exploited for DNA adductomic research by means of both triple quads and ion traps.33,43 
Employment of the neutral loss of 2’-deoxyribose by nucleosides, and the potentially characteristic 
loss of protonated bases (as reported by Inagaki and co-workers35) during DNA adduct fragmentation, 
could prove to be very rewarding as it allows analysts to focus their attention on the detection of 
potential DNA adduct biomarkers exclusively by ignoring all non-DNA adduct originating ions and 
molecules. 
Chromatographic Innovations 
As MS is usually coupled to chromatography, further advances could still be achieved by means of 
modern LC techniques. Within this framework, the use of capillary or nano capillary LC coupled to 
micro- or nano-ESI-MS could provide a rise in sensitivity.14,31 Due to the lower sample flow rates of 
capillary LC, the ionization and ion sampling efficiency in the electrospray source increase 
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significantly, resulting in a higher amount of ions in the MS system, an improved sensitivity and low 
mass detection limits.14 With micro- or nano-ESI, a higher electrospray efficiency and improved MS 
sensitivity are achieved in the same manner.68 Both (nano) capillary LC and micro- or nano-ESI-MS 
have been implemented for targeted DNA adduct analysis69-71 and allow sensitive DNA adduct 
analysis with a limited amount of sample.  
To eliminate non-altered nucleosides from the sample, two-dimensional (2D-)LC can be 
implemented.71 2D-LC is another on-line chromatography application that could definitely assist with 
detailed DNA adduct mapping because this technique allows one sample (or its most interesting 
‘section’) to be chromatographically separated twice (with 2 different columns), significantly adding to 
the separation power required for the analysis of complex biological samples like DNA. 2D-LC has 
already demonstrated its potential in metabolomics and proteomics72, and has been used for DNA 
adductomics at least once by Singh et al., who used a trap column to isolate PAH-dihydrodiolepoxide 
DNA adducts in order to facilitate subsequent separation by means of an analytical column 
thereafter.31 This approach enabled an increased sample throughput and a significant reduction of 
ionisation suppression and other matrix effects. Besides the elimination of unmodified DNA building 
blocks by means of a trap column, which significantly enhances the sensitivity of the analysis and also 
reduces the risk of artifacts14, 2D-LC also has the potential to assist with the combined and more 
adequate separation of different types of DNA adducts with different chemical attributes during one 
single chromatographic run when using two analytical columns. Unfortunately, according to the 
available literature, this has not been investigated yet. 
An additional technique that could be used to achieve an increase in sensitivity, consists of 
miniaturized separation techniques like LC-chip.31 This state-of-the-art development improves 
sensitivity by a gain in ionization efficiency and also significantly reduces the required sample size.73,74 
However, up to date, there are very few promising papers on DNA adduct analysis by means of LC-
chip MS, although the technique was introduced over a decade ago. It appears that the specialized 
nature of LC-chip technology and the need for specific LC and MS equipment may pose important 
restrictions for its widespread application. Although the technique definitely seems very promising for 
DNA adduct biomarker research, its optimisation and subsequent application seems to be rather 
complex and difficult; e.g. Bani-Yaseen et al. documented persistent problems with the separation of 
similar molecular structures.75 In contrast, Vouros and co-workers were able to use (commercialized) 
HPLC-chip MS methodology quite easily for the detection of dG-C8-4-ABP (a 4-aminobiphenyl DNA 
adduct), although they do not discuss its optimisation and practical use in detail.69  
Unfortunately, none of the above-mentioned techniques have been applied for untargeted DNA 
adductome mapping, merely leaving us with the promise of a giant leap forward in this field of 
research. It has, at least in part, been demonstrated for targeted DNA adduct analysis, but still needs 
to be established and confirmed for DNA adductomics purposes. 
 
PRACTICAL CONSIDERATIONS FOR (MASS SPECTROMETRY-BASED) DNA ADDUCTOME 
MAPPING  
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Internal Standards  
In recent years, the sensitivity of MS for DNA adduct quantitation purposes has increased significantly. 
The use of stable isotope labeled internal standards has provided a means to quantitate with high 
accuracy.13,14,28 An internal standard can be manufactured by replacing one or several atoms in the 
DNA adduct structure with their 2H, 13C, 15N or 18O isotopes. Due to the nearly identical chemical 
characteristics, these types of internal standards are well-suited for correction of variation due to 
losses during sample handling and preparation, local matrix effects, and possible fluctuations in 
sensitivity during analysis.14,28 In addition, the use of labeled (and unlabeled) (internal) standards 
facilitates compound identification by enabling comparison of the retention times that were obtained 
for different compounds.  
Unfortunately, appropriate internal standards for DNA adducts are not always easily obtained 
commercially.12 Furthermore, there may be some concerns regarding the stability of the labeled 
internal standards.14 Some deuterated DNA adduct analogues (e.g. d2-O6CMG) lack chemical stability 
and are prone to decomposition due to exchange of deuterium for hydrogen.14,54 The stability of 13C, 
15N and 18O labeled DNA adducts seems to be less cause for concern, as their degradation likely 
parallels the breakdown of their unlabeled counterparts.28 Furthermore, the internal standard should 
ideally differ in mass by 3 units from that of the compound under investigation. Hence, the use of 13C, 
15N and 18O labeled DNA bases is the obvious choice of internal standards. 
If there is no appropriate and stable internal standard available at the time, analysis and 
quantitation by means of an external calibration line offers a possible alternative, although less 
accurate approach for DNA adduct quantitation.14 However, this offers no scope for correction due to 
sample preparation issues. 
DNA Adduct Stability 
Sufficient knowledge on chemical stability of DNA adducts in biomarker studies is extremely important 
for correct interpretation of results.10,13 However, it appears that only a limited number of studies have 
studied the stability of a limited number of adduct types, which was discussed in detail by Himmelstein 
et al.12 DNA adduct stability depends on several factors including pH (e.g. M1dG is not stable under 
alkaline conditions76) and composition of storage buffers (e.g. Tris buffer induces M1dG instability77). 
Sample matrix (e.g. embedded in liver vs. kidney or other sample types78), sample processing (e.g. 
contamination by RNA can add to N7-methylguanine levels79), storage temperature (M1dG and 
benzo(a)pyrene DNA adducts, among others77,80) and, last but not least, DNA adduct type or chemical 
composition (e.g. O6-methylguanine appears to be more stable than N7-methylguanine and N3-
methylguanine81) also influence DNA adduct stability. In contrast, it appears that the number of 
freeze-thaw cycles and long term storage might not significantly reduce DNA adduct stability.82-84  
In order to avoid incorrect interpretation and loss of results, sample handling and storage should 
be considered in a case-by-case manner and executed carefully and consistently. To improve 
knowledge on DNA adduct stability, researchers should opt to conduct more DNA adduct stability 
studies focusing on different DNA adduct types, sample handling and storage conditions; e.g. taking 
the use of certain DNA buffers and the optimum storage temperature into account. In the meantime, 
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DNA should preferably be stored at -80°C, whilst evaporation to dryness may prevent early 
decomposition of DNA adducts.12 
Sample Preparation 
Sample preparation is considered to be one of the most critical steps in analytical chemistry in general, 
but in particular for DNA adduct quantitation since DNA adducts are embedded in a complex matrix of 
abundantly present unmodified DNA building blocks.28 To enable the simultaneous detection of a 
multitude of DNA adducts, sample preparation should be kept to a minimum, as extensive sample 
preparation procedures may induce artefacts (e.g. formation of oxo-dG during sample preparation), 
loss of sample and relevant information (due to e.g. instability issues). In addition, sample preparation 
(clean-up and enrichment) can be quite time consuming and labour intensive. However, sufficient 
release of DNA adducts from the DNA sequence (DNA hydrolysis efficiency), enrichment and removal 
of unwanted matrix constituents are indispensable.12,14,28  
DNA adducts can be detected individually as adducted nucleotides, nucleosides or nucleobases 
upon DNA hydrolysis, DNA adduct extraction and enrichment. The choice of measuring either 
adducted oligonucleotides, nucleotides, nucleosides or nucleobases greatly influences sample 
preparation needs. Analysis of (oligo-)nucleotides is least common and requires enzymatic digestion 
of DNA. Likewise, analysis of nucleosides requires enzymatic digestion and is the most common 
method of sample preparation for mass spectrometry-based analyses. Thermally labile modified 
nucleobases can be released by means of thermal hydrolysis. More stable adducted nucleobases can 
be retrieved with thermal hydrolysis at high temperature or strong acid hydrolysis. By combining acid 
and thermal hydrolysis, both altered and unaltered nucleobases are cleaved from the DNA sequence. 
14 Nonetheless, Kato et al. found that a single approach may not release all adducts and had to 
employ two different enzymatic hydrolysis methods to their samples, resulting in a doubled 
workload.46 These procedures are lengthy and have multiple steps that may cause changes to the 
DNA and the adduct profile, which must be thoroughly investigated during method development. 
To improve the sensitivity, sample clean-up and enrichment upon DNA hydrolysis or digestion are 
highly recommended.12,27 The envisioned removal of unmodified DNA building blocks and interfering 
contaminants (e.g. highly polar compounds that interfere with ionization) is required to minimize signal 
and ionization suppression.14,28 Frequently utilized on- or off-line techniques for DNA adduct 
enrichment include immunoaffinity column purification, HPLC column switching and solid phase 
extraction.14,27,28 However, care must be taken with selection of the appropriate stationary phases and 
elution buffers to avoid degradation/loss of the adducts. In addition, immunoaffinity column purification 
can only be implemented prior to targeted analysis due to the specificity of the antibodies in use.85 
Therefore, this particular technique is only suited for targeted DNA adduct analyses, but not DNA 
adductomics. 
Study Design 
The choice of an appropriate study design is considered to be one of the most important factors in 
DNA adductomics studies. The exposome is very complex, dynamic, and continuously changing.4 
Therefore, measurement of the exposome or DNA adductome at one isolated moment in time will not 
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answer all related research questions. Thus, assessment of individual exposure requires longitudinal 
studies.2,10 According to Wild, full characterization of the individual exposome requires an extensive 
number of sequential measures throughout a lifetime, or at the least, a smaller number of measures 
to assess exposures over a series of extended periods.4 In addition, exposomics studies should also 
consider the interfering influence of other very important factors like sample handling, fixation, storage 
and tracking, lack of tissue homogeneity, differences in individual susceptibility and genetic 
polymorphisms.10,86 Consequently, only well thought-out long-term and large-scale (e.g. many 
individuals, appropriate controls and different tissue types) studies will enable correct and thorough 
assessment of the DNA adductome. 
Surrogate vs. Target Tissue  
Ideally, DNA adduct formation should be monitored in the considered target tissue. A technical and 
ethical difficulty is that target tissue is not always easily obtained and/or available. A possible solution 
to that problem is the use of appropriate surrogate tissues like blood, urine and exfoliated (e.g. buccal 
or gastrointestinal epithelial) cells, provided that DNA adduct levels in target and surrogate tissue are 
distinctly related and a sufficient amount of DNA can be collected. Typically, procedures use an initial 
amount of 100 µg DNA although some require a lot less; e.g. the most recent method by Kanaly et al. 
used 15 µg DNA per injection.45 If no data on correlation of particular DNA adducts in surrogate vs. 
target tissue are available, correlation studies should be performed during or prior to bio-monitoring 
studies. Researchers must also consider the possibility that a certain type of surrogate tissue may be 
more appropriate than others, or that a well-suited surrogate tissue simply does not exist.10,87 For 
example, although Wiencke et al.88 were able to demonstrate the use of mononuclear blood cells as 
an appropriate surrogate tissue for lung tissue to study tobacco-associated DNA adduct formation, 
Kriek and co-workers were unable to correlate PAH-DNA adduct levels in white blood cells and lung 
tissue in lung cancer patients.89 
Method Validation  
Over the past thirty years, several papers have reported the development of new methods for the 
detection of single or plural DNA adducts in different matrices. The use of analytical methods for DNA 
adduct detection and quantification in biomonitoring studies necessitates thorough evaluation of 
reliability and fit-for-purpose. This requires assured specificity, accuracy, precision and sensitivity, 
acceptable recovery and reproducibility, information about the assay and compound stability, and the 
assessment of detection and quantification limits.90 Moreover, intra- and interlaboratory variability 
need to be assessed and properly addressed.12 However, at present, detailed and specific guidelines 
concerning the validation and interpretation of validation parameters of an analytical method for the 
detection of DNA adducts or possible biomarkers do not exist.  
Since biomarkers could provide interesting opportunities for the pharmaceutical industry, both the 
U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) are aware of the 
urgency to establish proper validation guidelines for biomarker assays. In consequence, suitable 
guidelines are to be published as soon as possible.90,91 In 2013, the FDA published draft guidance for 
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industry on bioanalytical method validation. In this draft guidance, the agency stated the following: 
“The accuracy, precision, selectivity, range, reproducibility, and stability of a biomarker assay are 
important characteristics that define the method. The approach used for pharmacokinetic assays 
should be the starting point for validation of biomarker assays, although FDA realizes that some 
characteristics may not apply or that different considerations may need to be addressed”.90 In 
agreement, the EMA published a concept paper on good genomics biomarker practices in 201491, 
which acknowledged and documented the need for guidance concerning choice and proper use of 
technology and methodology for genomic biomarker analysis in a clinical setting. 
Since DNA adducts are regarded as biomarkers of exposure and (possible) biomarkers of effect, 
the future FDA and EMA guidelines could provide a basis for validation of DNA adduct detection 
methods as well. 
 
CONCLUSIONS 
The field of DNA adduct research is a highly promising area due to the proposed causal link between 
the prevalence of certain environmental genotoxins, the formation of DNA adducts and the onset of 
certain non-hereditary cancer types.8,9,25 Furthermore, DNA adduct research does not only enable 
investigation of genotoxin exposure, uptake and metabolism, but can also provide us with information 
on the individual rate of DNA repair and individual susceptibility to permanent DNA damage, 
mutagenesis and carcinogenesis.11,24 Luckily, a multidisciplinary approach and the continuously 
evolving field of analytical apparatus available provide us with the appropriate tools for extensive DNA 
adductomic research in several specialized areas of research. 
In recent years, DNA adductomics is slowly emerging as a new omics tool that aims to study the 
formation and prevalence of a multitude of DNA adducts in vitro or in vivo.45 Omics technology and 
methodology allows top-down exposome and DNA adductome mapping, enabling potential discovery 
of yet unknown DNA adduct biomarkers in different biological samples. Contrary to most other 
methods, MS analyses can reliably generate both qualitative and quantitative DNA adduct data.32 MS-
based DNA adductomics therefore is particularly suited for research on the exposure of the human 
body to both known and unknown endo- and exogenous hazardous chemicals and any subsequently 
formed DNA adducts.27 Nevertheless, the search for answers does not end with DNA adduct mapping 
or biomarker establishment, as the described top-down approach does not evidently link genotoxin 
exposure to a certain environmental factor as a causal risk factor on the one hand, or disease 
outcome on the other.4 Any information obtained from top-down omics studies will only prove its value 
if combined with bottom-up targeted analyses in both long-term studies and purposeful short-term 
intervention studies.2,4 In addition, epidemiological information on human exposure to genotoxins or 
certain environmental factors by means of validated questionnaires or modern tracking technologies 
does still prove its worth.2 Hence, there is a clear need for large-scale and highly collaborative high 
resolution hybrid MS-based DNA adductomic studies combining the knowledge and effort of different 
researchers (e.g. epidemiologists, clinicians, pathologists, analysts and statisticians) to further unravel 
the non-genetic basis of chronic disease initiation and development due to genotoxin exposure. The 
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earlier discussion on study design, DNA adduct stability issues and method validation has clarified 
that DNA adductomic studies should not be embarked upon without a prudent hands-on approach, 
distinctly underlining the importance of multidisciplinary research. 
Insufficient knowledge of DNA adduct fragmentation patterns and limited availability of DNA adduct 
standards currently act as a bottleneck for the full characterization and correct identification of 
untargeted and unknown DNA adducts with MS.27 In this context, the need for accurate mass 
measurements is indisputable, whereas the establishment of a database to assemble all information 
on chemical structure and characteristics of DNA adducts, fragmentation patterns, stability, 
prevalence and origin (= initiating genotoxin + route of exposure) would provide a major advance by 
facilitating investigation of DNA adduct formation and its potential role in different pathophysiological 
pathways.  
Different research groups have explored triple quadrupole MS/MS, ion trap MS, TOF HRMS and 
orbitrap HRMS for DNA adductomics purposes. Up until now, triple quad and ion trap technology 
have been applied most frequently as MSn accommodates the need for low level DNA adduct 
measurements. However, for untargeted omics applications HRMS is the more rational choice since 
accurate mass measurements simplify compound identification. A relatively recent trend in MS 
technology is the more widely spread and commercial use of hybrid MS instruments that combine the 
accuracy of HRMS with the specificity and sensitivity of MSn. Accordingly, these hybrid MS 
instruments currently bring the best to the world of MS DNA adductomics, although additional work is 
required to further optimize the use of MS for DNA adductome mapping.  
Hybrid HRMS/MS systems are particularly well suited for the detection and tentative identification 
of unknowns because the implementation of accurate mass measurements with HRMS offers a major 
advantage over low resolution MS to accurately study the obtained fragmentation pattern of an 
unknown compound. After all, accurate mass measurements provide essential information on the 
exact mass of the precursor and fragments, their elemental composition and thus also the unknown 
identity of the precursor. In the field of DNA adduct research, the development and use of neutral loss 
HRMS/MS methodologies can push the investigation of unknown DNA adducts. By means of neutral 
loss, DNA adducts can be recognised due to the loss of a typical fragment; the loss of a nucleobase 
(DNA adduct research at the nucleobase level) or the deoxyribose moiety (DNA adduct research at 
nucleoside level) upon fragmentation of the precursor. Further in-depth investigation of the remaining 
fragments can then provide more information on the presence and exact chemical composition of 
both known and unknown DNA adducts in different sample types.33 At the time, the number of 
published DNA adductomics methods that make use of hybrid HRMS/MS technology are very limited 
(n = 2).32,66 However, due to the still ongoing establishment of these hybrid MS systems in the field, 
the number of DNA adductomics applications could increase significantly in the near future. 
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